Figure 3From: Are we HER-ting for innovation in neoadjuvant breast cancer trial design?Decision tree from GeparQuinto study. B, bevacizumab; EC, epirubicin-cyclophosphamide; H, trastuzumab; Her-2, human epidermal growth factor receptor 2; L, lapatinib; Pw, paclitaxel weekly; T, docetaxel. Reprinted with permission from GBG (German Breast Group).Back to article page